Catalyst Gross Profit from 2010 to 2025

CPRX Stock

USD 24.23 1.07 4.62%

Catalyst Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Catalyst Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2004-12-31

Previous Quarter

109.4 M

Current Value

120.2 M

Quarterly Volatility

29.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 311.4 M or Operating Income of 204.9 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0 or PTB Ratio of 3.23. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Catalyst Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Catalyst Pharmaceuticals minus its cost of goods sold. It is profit before Catalyst Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Catalyst Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 421.11 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Catalyst Gross Profit Regression Statistics

	Arithmetic Mean	103,659,251
	Geometric Mean	0.00
	Coefficient Of Variation	150.93
	Mean Deviation	120,132,149
	Median	500,000
	Standard Deviation	156,450,813
	Sample Variance	24476.9T
	Range	455.4M
	R-Value	0.84
	Mean Square Error	7589.6T
	R-Squared	0.71
	Significance	0.000041
	Slope	27,701,080
	Total Sum of Squares	367152.9T

Catalyst Gross Profit History

	2025	444 M
	2024	422.9 M
	2023	313.7 M
	2022	179.8 M
	2021	118.9 M
	2020	102 M
	2019	87.5 M

Other Fundumenentals of Catalyst Pharmaceuticals

Gross Profit Margin

Catalyst Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Accounts Payable	Common Stock	Property Plant Equipment	Net Receivables	Net Tangible Assets	Short Term Investments	Capital Surpluse	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock	Current Deferred Revenue	Short Term Debt
Total Assets		1.0	-0.97	0.99	0.98	0.93	0.95	0.45	0.36	0.93	0.92	-0.53	0.58	0.99	0.96	0.8	0.94	-0.87	0.3
Total Stockholder Equity	1.0		-0.97	0.98	0.99	0.93	0.95	0.45	0.37	0.94	0.92	-0.52	0.58	0.99	0.96	0.81	0.95	-0.85	0.3
Net Debt	-0.97	-0.97		-0.95	-0.99	-0.88	-0.85	-0.46	-0.4	-0.82	-0.91	0.53	-0.6	-0.96	-0.98	-0.67	-0.92	0.81	-0.26
Total Liab	0.99	0.98	-0.95		0.97	0.92	0.94	0.45	0.34	0.92	0.93	-0.59	0.59	0.97	0.93	0.77	0.91	-0.92	0.35
Total Current Assets	0.98	0.99	-0.99	0.97		0.89	0.89	0.46	0.39	0.87	0.91	-0.5	0.59	0.98	0.98	0.73	0.94	-0.82	0.27
Retained Earnings	0.93	0.93	-0.88	0.92	0.89		0.88	0.13	0.28	0.88	0.8	-0.67	0.29	0.96	0.92	0.84	0.91	-0.85	0.36
Accounts Payable	0.95	0.95	-0.85	0.94	0.89	0.88		0.44	0.25	0.98	0.86	-0.51	0.56	0.94	0.84	0.87	0.9	-0.85	0.31
Common Stock	0.45	0.45	-0.46	0.45	0.46	0.13	0.44		0.38	0.39	0.63	0.11	0.97	0.35	0.31	0.1	0.31	-0.36	0.05
Property Plant Equipment	0.36	0.37	-0.4	0.34	0.39	0.28	0.25	0.38		0.21	0.53	-0.07	0.45	0.33	0.36	0.03	0.2	-0.09	0.19
Net Receivables	0.93	0.94	-0.82	0.92	0.87	0.88	0.98	0.39	0.21		0.8	-0.45	0.49	0.93	0.84	0.93	0.91	-0.83	0.4
Net Tangible Assets	0.92	0.92	-0.91	0.93	0.91	0.8	0.86	0.63	0.53	0.8		-0.51	0.76	0.88	0.84	0.57	0.76	-0.84	0.18
Short Term Investments	-0.53	-0.52	0.53	-0.59	-0.5	-0.67	-0.51	0.11	-0.07	-0.45	-0.51		-0.1	-0.56	-0.53	-0.36	-0.49	0.61	-0.13
Capital Surpluse	0.58	0.58	-0.6	0.59	0.59	0.29	0.56	0.97	0.45	0.49	0.76	-0.1		0.49	0.45	0.19	0.43	-0.5	0.06
Net Invested Capital	0.99	0.99	-0.96	0.97	0.98	0.96	0.94	0.35	0.33	0.93	0.88	-0.56	0.49		0.97	0.84	0.96	-0.85	0.32
Net Working Capital	0.96	0.96	-0.98	0.93	0.98	0.92	0.84	0.31	0.36	0.84	0.84	-0.53	0.45	0.97		0.74	0.95	-0.78	0.28
Long Term Investments	0.8	0.81	-0.67	0.77	0.73	0.84	0.87	0.1	0.03	0.93	0.57	-0.36	0.19	0.84	0.74		0.87	-0.72	0.46
Capital Stock	0.94	0.95	-0.92	0.91	0.94	0.91	0.9	0.31	0.2	0.91	0.76	-0.49	0.43	0.96	0.95	0.87		-0.77	0.36
Current Deferred Revenue	-0.87	-0.85	0.81	-0.92	-0.82	-0.85	-0.85	-0.36	-0.09	-0.83	-0.84	0.61	-0.5	-0.85	-0.78	-0.72	-0.77		-0.39
Short Term Debt	0.3	0.3	-0.26	0.35	0.27	0.36	0.31	0.05	0.19	0.4	0.18	-0.13	0.06	0.32	0.28	0.46	0.36	-0.39

Click cells to compare fundamentals

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	422.9 M	444 M
Gross Profit Margin	0.86	0.90

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC